Stock Analysis on Net

Amgen Inc. (NASDAQ:AMGN)

Analysis of Liquidity Ratios
Quarterly Data

Microsoft Excel

Liquidity Ratios (Summary)

Amgen Inc., liquidity ratios (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Current ratio 1.65 2.86 2.77 3.14 1.41 1.68 1.53 1.44 1.59 1.64 1.31 1.66 1.81 2.28 2.18 1.59 1.44 2.89 2.89 2.77
Quick ratio 0.99 2.41 2.34 2.62 0.95 1.17 0.99 0.90 1.06 1.19 0.86 1.16 1.30 1.65 1.60 1.10 1.01 2.28 2.41 2.37
Cash ratio 0.60 2.05 2.00 2.22 0.59 0.80 0.57 0.51 0.66 0.87 0.55 0.82 0.91 1.24 1.09 0.68 0.69 1.94 2.05 2.07

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Amgen Inc. current ratio improved from Q2 2023 to Q3 2023 but then deteriorated significantly from Q3 2023 to Q4 2023.
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Amgen Inc. quick ratio improved from Q2 2023 to Q3 2023 but then deteriorated significantly from Q3 2023 to Q4 2023.
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Amgen Inc. cash ratio improved from Q2 2023 to Q3 2023 but then deteriorated significantly from Q3 2023 to Q4 2023.

Current Ratio

Amgen Inc., current ratio calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Current assets 30,332 48,477 47,380 44,703 22,186 24,062 19,322 18,520 19,385 24,380 19,099 21,299 21,144 22,661 22,895 18,813 18,440 31,051 30,746 35,151
Current liabilities 18,392 16,954 17,097 14,215 15,687 14,331 12,618 12,886 12,184 14,842 14,585 12,869 11,653 9,953 10,523 11,827 12,835 10,737 10,622 12,706
Liquidity Ratio
Current ratio1 1.65 2.86 2.77 3.14 1.41 1.68 1.53 1.44 1.59 1.64 1.31 1.66 1.81 2.28 2.18 1.59 1.44 2.89 2.89 2.77
Benchmarks
Current Ratio, Competitors2
AbbVie Inc. 0.87 0.96 0.89 0.96 0.96 0.93 0.84 0.82 0.79 1.01 0.91 0.83 0.84 0.95 0.86 3.14 3.18 1.15 0.89 1.04
Bristol-Myers Squibb Co. 1.43 1.18 1.39 1.42 1.25 1.42 1.44 1.32 1.52 1.47 1.54 1.56 1.58 1.67 1.47 1.66 1.60 3.83 3.88 1.93
Eli Lilly & Co. 0.94 1.05 1.13 1.30 1.05 1.13 1.10 1.27 1.23 1.30 1.15 1.42 1.40 1.36 1.22 1.11 1.16 1.17 1.13 1.12
Gilead Sciences Inc. 1.43 1.34 1.02 1.28 1.29 1.30 1.43 1.48 1.27 1.37 1.36 1.37 1.40 3.25 2.33 3.04 3.10 2.96 3.76 3.62
Johnson & Johnson 1.16 1.21 1.12 1.07 0.99 1.43 1.42 1.39 1.35 1.34 1.39 1.28 1.21 1.48 1.25 1.31 1.26 1.26 1.33 1.44
Merck & Co. Inc. 1.25 1.38 1.28 1.44 1.47 1.46 1.39 1.40 1.27 1.31 1.31 1.02 1.02 1.30 1.32 1.11 1.24 1.26 1.21 1.37
Pfizer Inc. 0.91 2.38 2.12 1.37 1.22 1.59 1.42 1.39 1.40 1.39 1.37 1.48 1.35 1.40 1.42 1.03 0.88 0.90 1.47 1.54
Regeneron Pharmaceuticals Inc. 5.69 5.18 5.45 5.45 5.06 5.36 5.12 4.76 3.56 3.71 3.57 3.12 3.63 3.89 2.12 4.21 3.67 4.03 3.88 4.58
Thermo Fisher Scientific Inc. 1.75 1.63 1.42 1.27 1.48 1.74 1.65 1.56 1.50 3.19 2.78 2.53 2.13 2.93 2.62 2.32 1.92 1.80 1.49 1.69
Vertex Pharmaceuticals Inc. 3.99 4.08 4.14 4.28 4.83 4.70 4.50 4.75 4.46 4.62 4.61 4.39 4.33 3.72 3.72 3.54 3.61 3.44 3.74 3.78

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
Current ratio = Current assets ÷ Current liabilities
= 30,332 ÷ 18,392 = 1.65

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Amgen Inc. current ratio improved from Q2 2023 to Q3 2023 but then deteriorated significantly from Q3 2023 to Q4 2023.

Quick Ratio

Amgen Inc., quick ratio calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Cash and cash equivalents 10,944 34,741 34,248 31,560 7,629 9,502 5,203 6,528 7,989 11,969 6,630 6,112 6,266 9,087 9,145 7,687 6,037 11,415 5,525 7,358
Marketable securities 1 1,676 1,976 1,980 16 48 952 1,452 4,454 4,381 3,273 2,276 325 2,874 9,438 16,233 18,943
Trade receivables, net 7,268 6,145 5,830 5,736 5,563 5,326 5,327 5,077 4,895 4,765 4,479 4,423 4,525 4,094 5,366 5,009 4,057 3,606 3,801 3,771
Total quick assets 18,212 40,886 40,078 37,297 14,868 16,804 12,510 11,621 12,932 17,686 12,561 14,989 15,172 16,454 16,787 13,021 12,968 24,459 25,559 30,072
 
Current liabilities 18,392 16,954 17,097 14,215 15,687 14,331 12,618 12,886 12,184 14,842 14,585 12,869 11,653 9,953 10,523 11,827 12,835 10,737 10,622 12,706
Liquidity Ratio
Quick ratio1 0.99 2.41 2.34 2.62 0.95 1.17 0.99 0.90 1.06 1.19 0.86 1.16 1.30 1.65 1.60 1.10 1.01 2.28 2.41 2.37
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc. 0.63 0.71 0.63 0.66 0.69 0.69 0.61 0.56 0.56 0.75 0.65 0.61 0.60 0.68 0.58 2.88 2.91 0.92 0.64 0.78
Bristol-Myers Squibb Co. 1.04 0.77 0.94 1.01 0.87 0.98 1.07 1.03 1.20 1.16 1.16 1.25 1.28 1.43 1.26 1.38 1.26 3.63 3.61 1.64
Eli Lilly & Co. 0.52 0.58 0.63 0.79 0.63 0.71 0.67 0.77 0.80 0.79 0.67 0.83 0.85 0.79 0.68 0.64 0.68 0.66 0.67 0.65
Gilead Sciences Inc. 1.06 0.98 0.78 0.95 0.99 0.96 1.06 1.06 0.95 1.01 1.05 0.99 1.08 2.93 2.09 2.78 2.86 2.74 3.41 3.32
Johnson & Johnson 0.82 0.86 0.84 0.81 0.71 1.10 1.09 1.06 1.04 1.03 1.04 0.97 0.91 1.17 0.92 0.98 0.94 0.93 0.95 1.01
Merck & Co. Inc. 0.68 0.83 0.74 0.90 0.93 0.90 0.85 0.84 0.73 0.78 0.75 0.58 0.58 0.77 0.84 0.66 0.78 0.80 0.75 0.88
Pfizer Inc. 0.50 1.78 1.59 0.88 0.80 1.18 1.02 0.95 1.00 0.99 0.91 0.88 0.78 0.93 0.98 0.60 0.50 0.50 0.71 0.72
Regeneron Pharmaceuticals Inc. 4.82 4.31 4.53 4.54 4.16 4.37 4.20 3.95 2.98 3.03 2.92 2.39 2.86 3.02 1.61 3.38 2.81 3.14 2.99 3.66
Thermo Fisher Scientific Inc. 1.27 1.13 0.89 0.80 1.06 1.06 0.98 0.97 1.00 2.37 1.92 1.70 1.63 2.16 1.83 1.48 1.19 0.97 0.85 0.89
Vertex Pharmaceuticals Inc. 3.60 3.74 3.82 3.95 4.46 4.28 4.14 4.37 4.04 4.21 4.16 4.06 4.02 3.46 3.47 3.27 3.33 3.20 3.51 3.54

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 18,212 ÷ 18,392 = 0.99

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Amgen Inc. quick ratio improved from Q2 2023 to Q3 2023 but then deteriorated significantly from Q3 2023 to Q4 2023.

Cash Ratio

Amgen Inc., cash ratio calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Cash and cash equivalents 10,944 34,741 34,248 31,560 7,629 9,502 5,203 6,528 7,989 11,969 6,630 6,112 6,266 9,087 9,145 7,687 6,037 11,415 5,525 7,358
Marketable securities 1 1,676 1,976 1,980 16 48 952 1,452 4,454 4,381 3,273 2,276 325 2,874 9,438 16,233 18,943
Total cash assets 10,944 34,741 34,248 31,561 9,305 11,478 7,183 6,544 8,037 12,921 8,082 10,566 10,647 12,360 11,421 8,012 8,911 20,853 21,758 26,301
 
Current liabilities 18,392 16,954 17,097 14,215 15,687 14,331 12,618 12,886 12,184 14,842 14,585 12,869 11,653 9,953 10,523 11,827 12,835 10,737 10,622 12,706
Liquidity Ratio
Cash ratio1 0.60 2.05 2.00 2.22 0.59 0.80 0.57 0.51 0.66 0.87 0.55 0.82 0.91 1.24 1.09 0.68 0.69 1.94 2.05 2.07
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc. 0.34 0.38 0.27 0.24 0.31 0.36 0.29 0.23 0.28 0.43 0.30 0.31 0.30 0.33 0.25 2.50 2.56 0.61 0.32 0.38
Bristol-Myers Squibb Co. 0.55 0.33 0.43 0.49 0.42 0.48 0.63 0.66 0.78 0.73 0.68 0.75 0.83 1.03 0.92 0.95 0.84 3.10 3.02 0.99
Eli Lilly & Co. 0.11 0.11 0.15 0.23 0.13 0.18 0.18 0.19 0.26 0.28 0.22 0.26 0.29 0.30 0.20 0.14 0.21 0.15 0.20 0.19
Gilead Sciences Inc. 0.64 0.57 0.48 0.56 0.57 0.54 0.61 0.62 0.56 0.56 0.64 0.58 0.65 2.52 1.79 2.34 2.50 2.39 3.03 2.97
Johnson & Johnson 0.50 0.53 0.53 0.54 0.42 0.75 0.73 0.70 0.70 0.70 0.65 0.60 0.59 0.79 0.52 0.54 0.54 0.51 0.49 0.53
Merck & Co. Inc. 0.28 0.38 0.27 0.45 0.54 0.49 0.44 0.40 0.34 0.42 0.39 0.26 0.30 0.36 0.50 0.32 0.47 0.39 0.35 0.47
Pfizer Inc. 0.27 1.42 1.29 0.55 0.54 0.82 0.70 0.61 0.73 0.71 0.61 0.51 0.47 0.64 0.70 0.31 0.26 0.25 0.40 0.39
Regeneron Pharmaceuticals Inc. 3.17 2.75 2.88 2.89 2.46 2.44 2.49 2.34 1.45 1.56 1.05 1.09 1.33 1.29 0.85 1.95 1.53 1.63 1.56 2.14
Thermo Fisher Scientific Inc. 0.58 0.43 0.22 0.22 0.50 0.26 0.17 0.23 0.33 1.55 1.01 0.80 1.00 1.21 0.97 0.54 0.39 0.22 0.30 0.19
Vertex Pharmaceuticals Inc. 3.16 3.31 3.35 3.44 3.93 3.74 3.62 3.78 3.51 3.64 3.65 3.56 3.55 3.07 3.03 2.72 2.85 2.88 3.14 3.14

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 10,944 ÷ 18,392 = 0.60

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Amgen Inc. cash ratio improved from Q2 2023 to Q3 2023 but then deteriorated significantly from Q3 2023 to Q4 2023.